Novavax (NASDAQ: NVAX) Settles Dispute with UK Health Security Agency

Novavax, Inc. recently disclosed a significant development in a Form 8-K filing submitted to the United States Securities and Exchange Commission. The Maryland-based biote

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Novavax’s 8K filing here.

About Novavax

(Get Free Report)

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.

Further Reading